Scientech Research LLC Protagonist Therapeutics, Inc Transaction History
Scientech Research LLC
- $502 Billion
- Q3 2024
A detailed history of Scientech Research LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Scientech Research LLC holds 14,527 shares of PTGX stock, worth $661,414. This represents 0.13% of its overall portfolio holdings.
Number of Shares
14,527Holding current value
$661,414% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$267 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$262 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$247 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$192 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$145 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.23B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...